• Reference Citation Analysis
  • v
  • v
  • Find an Article
Download
Number Select Citation Analysis
1 Sanli Y, Denizmen D, Subramaniam RM. Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: (177)Lu-DOTATATE. PET Clin 2023;18:201-14. [PMID: 36858745 DOI: 10.1016/j.cpet.2022.11.002] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/02/2023]
2 Zhou F, Yuan Z, Liu X, Yu K, Li B, Li X, Liu X, Cheng G. Evaluation of atrial anatomical remodeling in atrial fibrillation with machine-learned morphological features. Int J Comput Assist Radiol Surg 2023;18:603-10. [PMID: 36272019 DOI: 10.1007/s11548-022-02776-z] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 11/29/2022]
3 Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci 2023;44:222-36. [PMID: 36828759 DOI: 10.1016/j.tips.2023.01.003] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/25/2023]
4 Zhang L, Pan Z, Wang H, Shi C, Lin X, Cao Y. The prognostic significance of serum lactate dehydrogenase for patients with small cell lung cancer treated first-line therapy: a retrospective analysis of 163 consecutive cases.. [DOI: 10.21203/rs.3.rs-2620618/v1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/18/2023]
5 Viganò M, La Milia M, Grassini MV, Pugliese N, De Giorgio M, Fagiuoli S. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers (Basel) 2023;15:1766. [DOI: 10.3390/cancers15061766] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/17/2023]  Open
6 Gagliardi F, Baldini E, Lori E, Cardarelli S, Pironi D, Lauro A, Tripodi D, Palumbo P, D’armiento E, Cavallaro G, Polistena A, D’orazi V, Sibio S, Fallahi P, Antonelli A, D’andrea V, Ulisse S, Sorrenti S. Insights on the Association between Thyroid Diseases and Colorectal Cancer. J Clin Med 2023;12:2234. [DOI: 10.3390/jcm12062234] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/15/2023]  Open
7 Ben Guebila M, Wang T, Lopes-Ramos CM, Fanfani V, Weighill D, Burkholz R, Schlauch D, Paulson JN, Altenbuchinger M, Shutta KH, Sonawane AR, Lim J, Calderer G, van IJzendoorn DGP, Morgan D, Marin A, Chen CY, Song Q, Saha E, DeMeo DL, Padi M, Platig J, Kuijjer ML, Glass K, Quackenbush J. The Network Zoo: a multilingual package for the inference and analysis of gene regulatory networks. Genome Biol 2023;24:45. [PMID: 36894939 DOI: 10.1186/s13059-023-02877-1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/11/2023]  Open
8 Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol 2023. [PMID: 36892833 DOI: 10.1001/jamaoncol.2022.7845] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/10/2023]
9 Kitsel Y, Cooke T, Sotirchos V, Sofocleous C. Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. Cancers (Basel) 2023;15:1679. [DOI: 10.3390/cancers15061679] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/11/2023]  Open
10 Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol 2023;:175586. [PMID: 36906141 DOI: 10.1016/j.ejphar.2023.175586] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/11/2023]
11 Fuchs JW, Schulte BC, Fuchs JR, Agulnik M. Targeted therapies for the treatment of soft tissue sarcoma. Front Oncol 2023;13. [PMID: 36969064 DOI: 10.3389/fonc.2023.1122508] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/11/2023]  Open
12 Lou E. Immunotherapy Success for Microsatellite Stable Colorectal Cancers-Searching for the Horizon. JAMA Oncol 2023. [PMID: 36892823 DOI: 10.1001/jamaoncol.2022.7786] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Indexed: 03/10/2023]
13 Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J Gastroenterol 2023; 29(9): 1395-1426 [DOI: 10.3748/wjg.v29.i9.1395] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Indexed: 03/07/2023]  Open
14 Hernandez Dominguez O, Yilmaz S, Steele SR. Stage IV Colorectal Cancer Management and Treatment. J Clin Med 2023;12. [PMID: 36902858 DOI: 10.3390/jcm12052072] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/08/2023]  Open
15 Ros J, Salva F, Dopazo C, López D, Saoudi N, Baraibar I, Charco R, Tabernero J, Elez E. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer 2023. [PMID: 36879000 DOI: 10.1038/s41416-023-02213-1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/08/2023]  Open
16 Park J, Xuan B, Jeong Y, Han G, Kim EB. Omega-3-Rich Fish-Oil-Influenced Mouse Gut Microbiome Shaped by Intermittent Consumption of Beef. Curr Microbiol 2023;80:119. [PMID: 36855004 DOI: 10.1007/s00284-023-03223-1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/02/2023]
17 Dekanić A, Babarović E, Brlić PK, Knežić M, Vuković AS, Mazor M, Jonjić N. The Prognostic Significance of Nectin-2 and Nectin-4 expression in glial tumors. Pathol Res Pract 2023. [DOI: 10.1016/j.prp.2023.154416] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Indexed: 03/19/2023]
18 Roze S, Bertrand N, Eberst L, Borget I. Projecting overall survival in health-economic models: uncertainty and maturity of data. Curr Med Res Opin 2023;39:367-74. [PMID: 36628431 DOI: 10.1080/03007995.2023.2167442] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 01/12/2023]
19 Wang J, Millstein J, Yang Y, Stintzing S, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Mancao C, Cremolini C, Liu T, Heinemann V, Falcone A, Shen L, Lenz HJ. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials. EClinicalMedicine 2023;57:101827. [PMID: 36816347 DOI: 10.1016/j.eclinm.2023.101827] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Indexed: 02/06/2023]  Open
20 Nie C, Xu W, Chen B, Lv H, Wang J, Liu Y, He Y, Wang S, Zhao J, Chen X. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. Clin Colorectal Cancer 2023;22:76-84. [PMID: 36564281 DOI: 10.1016/j.clcc.2022.11.005] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 12/03/2022]
21 Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, Guo J, Su W, Fan S, Tan P, Wang Y, Luo Y, Zhou H, Li J. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur J Cancer 2023;181:26-37. [PMID: 36628898 DOI: 10.1016/j.ejca.2022.12.004] [Cited by in Crossref: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 12/14/2022]
22 Victorino APOS, Meton F, Mardegan L, Festa J, Piranda DN, Araujo KB. Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. J Geriatr Oncol 2023. [DOI: 10.1016/j.jgo.2023.101477] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Indexed: 03/29/2023]
23 Cosso F, Lavacchi D, Fancelli S, Caliman E, Brugia M, Rossi G, Winchler C, Pillozzi S, Antonuzzo L. Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer. Anticancer Drugs 2023;34:451-4. [PMID: 36730636 DOI: 10.1097/CAD.0000000000001410] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/04/2023]
24 Thakur A, Kumar M. Integration of Human and Viral miRNAs in Epstein-Barr Virus-Associated Tumors and Implications for Drug Repurposing. OMICS 2023;27:93-108. [PMID: 36927073 DOI: 10.1089/omi.2023.0005] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/18/2023]
25 Udagawa S, Ooki A, Shinozaki E, Fukuda K, Yamaguchi K, Osumi H. Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. Cancers (Basel) 2023;15. [PMID: 36900264 DOI: 10.3390/cancers15051473] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/02/2023]  Open
26 Symons R, Daly D, Gandy R, Goldstein D, Aghmesheh M. Progress in the Treatment of Small Intestine Cancer. Curr Treat Options Oncol 2023. [PMID: 36826686 DOI: 10.1007/s11864-023-01058-3] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/25/2023]
27 Ma SX, Li L, Cai H, Guo TK, Zhang LS. Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review. World J Clin Oncol 2023; 14(2): 81-88 [PMID: 36908678 DOI: 10.5306/wjco.v14.i2.81] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Indexed: 02/21/2023]  Open
28 Tang YL, Li DD, Duan JY, Sheng LM, Wang X. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World J Gastroenterol 2023; 29(6): 926-948 [PMID: 36844139 DOI: 10.3748/wjg.v29.i6.926] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Indexed: 02/10/2023]  Open
29 Dinu IM, Mihăilă M, Diculescu MM, Croitoru VM, Turcu-Stiolica A, Bogdan D, Miron MI, Lungulescu CV, Alexandrescu ST, Dumitrașcu T, Buică F, Luca IN, Lungulescu C, Negulescu MC, Gramaticu IM, Cazacu IM, Croitoru AE. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. Medicina (Kaunas) 2023;59. [PMID: 36837551 DOI: 10.3390/medicina59020350] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/16/2023]
30 Stiefel R, Lehmann K, Winder T, Siebenhüner AR. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022? BMC Cancer 2023;23:148. [PMID: 36782152 DOI: 10.1186/s12885-023-10567-1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/15/2023]  Open
31 Matsumoto T, Ikoma T, Yamamura S, Miura K, Tsuduki T, Watanabe T, Nagai H, Takatani M, Yasui H. Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. Sci Rep 2023;13:2433. [PMID: 36765099 DOI: 10.1038/s41598-023-29706-6] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/12/2023]  Open
32 Kairey L, Leech B, El-Assaad F, Bugarcic A, Dawson D, Lauche R. The effects of kefir consumption on human health: a systematic review of randomized controlled trials. Nutr Rev 2023;81:267-86. [PMID: 35913411 DOI: 10.1093/nutrit/nuac054] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/01/2023]  Open
33 Maring JG, Eijsink JFH, Tichelaar FD, Veluwenkamp-Worawutputtapong P, Postma MJ, Touw DJ, de Groot JWB. Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review. Cancers (Basel) 2023;15. [PMID: 36831478 DOI: 10.3390/cancers15041135] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/12/2023]  Open
34 Kato T, Kudo T, Kagawa Y, Murata K, Ota H, Noura S, Hasegawa J, Tamagawa H, Ohta K, Ikenaga M, Miyazaki S, Komori T, Uemura M, Nishimura J, Hata T, Matsuda C, Satoh T, Mizushima T, Ohno Y, Yamamoto H, Doki Y, Eguchi H. Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. Sci Rep 2023;13:2331. [PMID: 36759648 DOI: 10.1038/s41598-022-24057-0] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/11/2023]  Open
35 Gohel S, Lavingia V. HER2 ‘neu’ promise for mCRC. IJMIO 2023;8:3-8. [DOI: 10.25259/ijmio_30_2022] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/05/2023]
36 Liu Q, Li S, Qiu Y, Zhang J, Rios FJ, Zou Z, Touyz RM. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. Front Cardiovasc Med 2023;10:1002438. [PMID: 36818331 DOI: 10.3389/fcvm.2023.1002438] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/05/2023]  Open
37 Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, Sobrero A. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol 2022;12:946850. [PMID: 36818675 DOI: 10.3389/fonc.2022.946850] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/05/2023]  Open
38 Bieuville M, Faugère D, Galibert V, Henard M, Dujon AM, Ujvari B, Pujol P, Roche B, Thomas F. Number of lifetime menses increases breast cancer occurrence in postmenopausal women at high familial risk. Front Ecol Evol 2023;11. [DOI: 10.3389/fevo.2023.912083] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 02/05/2023]  Open
39 He J, Liu Y, Liu C, Hu H, Sun L, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Fang M, Li E, Xu Y, Chen Y, Li J, Cui Y, Pan Z, Zhang S, Yuan Y, Ding K. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technol Cancer Res Treat 2023;22:15330338231152350. [PMID: 36727222 DOI: 10.1177/15330338231152350] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Indexed: 02/03/2023]  Open
40 Cao S, Zhang W, Pan H, Huang Z, Guo M, Zhang L, Xu X, Saw PE. Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy. Acta Biomater 2023;157:500-10. [PMID: 36535568 DOI: 10.1016/j.actbio.2022.12.022] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 12/23/2022]
41 Wang M, Su J, Lu J, Yang Z, Wang J, Zhong Y, Zeng T, Shen K, Lin S. Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis? Clin Res Hepatol Gastroenterol 2023;47:102078. [PMID: 36627051 DOI: 10.1016/j.clinre.2023.102078] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 01/09/2023]
42 Mahajan A, Chakrabarty N, Majithia J, Ahuja A, Agarwal U, Suryavanshi S, Biradar M, Sharma P, Raghavan B, Arafath R, Shukla S. Multisystem Imaging Recommendations/Guidelines: In the Pursuit of Precision Oncology. Indian J Med Paediatr Oncol 2023;44:002-025. [DOI: 10.1055/s-0043-1761266] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 03/08/2023]  Open
43 Zhu Q, Rao W, Huo J, Li Z, Wang S, Qiu W, Guan G, Xin Y, Fan N, Cai J, Wu L. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center. BMC Gastroenterol 2023;23:28. [PMID: 36726082 DOI: 10.1186/s12876-023-02661-2] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/03/2023]  Open
44 Le DT, Diaz LA, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O’neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Élez E, Al-batran S, Boland PM, Cui Y, Leconte P, Marinello P, André T. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer 2023. [DOI: 10.1016/j.ejca.2023.02.016] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Indexed: 02/26/2023]
45 Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study. ESMO Open 2023;8:100748. [PMID: 36603521 DOI: 10.1016/j.esmoop.2022.100748] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 01/05/2023]  Open
46 Sun B, Chen H, Wang X, Chen T. Regorafenib induces Bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export. Cell Death Dis 2023;9:37. [PMID: 36720853 DOI: 10.1038/s41420-023-01338-9] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 02/02/2023]
47 San-Román-Gil M, Torres-Jiménez J, Pozas J, Esteban-Villarrubia J, Albarrán-Fernández V, Álvarez-Ballesteros P, Chamorro-Pérez J, Rosero-Rodríguez D, Orejana-Martín I, Martínez-Delfrade Í, Reguera-Puertas P, Fuentes-Mateos R, Ferreiro-Monteagudo R. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765821 DOI: 10.3390/cancers15030863] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 01/31/2023]  Open
48 Pellegrino F, Granata V, Fusco R, Grassi F, Tafuto S, Perrucci L, Tralli G, Scaglione M. Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists. Tomography 2023;9:217-46. [PMID: 36828370 DOI: 10.3390/tomography9010018] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Indexed: 01/31/2023]  Open
49 Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 2023;41:460-71. [PMID: 36351210 DOI: 10.1200/JCO.22.01423] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 11/11/2022]  Open
50 zhang X, Zhang A, Zhang J, Xia H, Gu X, Ding L, Zhang X, Yin W. The efficacy and adverse events of regorafenib in advanced gastrointestinal stromal tumors after imatinib and sunitinib failure: a systemic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2391619/v1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Indexed: 01/22/2023]
PrevPage 1 of 61 123456061Next
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA